A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Clinical trial NCT05679258 · COMPLETED
Trial details
- NCT number
- NCT05679258
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-31
- Primary completion
- 2024-03-16
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.